Pancreatic Cancer Research

ResearcherHeidelberg UniversityNo recent work listed

Svetlana Karakhanova

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5087876902. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2013: 2 papers · 2014: 3 papers · 2015: 4 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 1 paper

Papers 14

  1. Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer. Last author DOI 10.1080/2162402x.2022.2043037↗
  2. Inhibition of miR30a-3p by sulforaphane enhances gap junction intercellular communication in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.10.042↗
  3. Novel plant microRNAs from broccoletti sprouts do not show cross-kingdom regulation of pancreatic cancer. Co-author DOI 10.18632/oncotarget.27527↗
  4. MicroRNA-365a-3p inhibits c-Rel-mediated NF-κB signaling and the progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.025↗
  5. The novel mitochondria-targeted antioxidant SkQ1 modulates angiogenesis and inflammatory micromilieu in a murine orthotopic model of pancreatic cancer. Last author DOI 10.1002/ijc.30054↗
  6. Reduced retinoids and retinoid receptors' expression in pancreatic cancer: A link to patient survival. Co-author DOI 10.1002/mc.22158↗
  7. Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma. First author DOI 10.1007/s00210-015-1147-9↗
  8. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Co-author DOI 10.1038/bjc.2015.72↗
  9. Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. Co-author DOI 10.1080/2162402x.2014.998519↗
  10. Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. Last author DOI 10.1007/s00262-013-1485-8↗
  11. Interlude of cGMP and cGMP/protein kinase G type 1 in pancreatic adenocarcinoma cells. Co-author DOI 10.1097/mpa.0000000000000104↗
  12. Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma. Co-author DOI 10.3390/ijms15034104↗
  13. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. First author DOI 10.1002/ijc.27990↗
  14. Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer. Last author DOI 10.4161/onci.25736↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alexandr V. Bazhin · 8 shared papers, 2013–2022 · strength 0.52
  2. Jens Werner · 9 shared papers, 2013–2016 · strength 0.46
  3. Christina Georgikou · 3 shared papers, 2019–2020 · strength 0.29
  4. Libo Yin · 3 shared papers, 2019–2020 · strength 0.29
  5. Xi Xiao · 3 shared papers, 2019–2020 · strength 0.29
  6. Ingrid Herr · 3 shared papers, 2019–2020 · strength 0.29
  7. Li Liu · 2 shared papers, 2019–2020 · strength 0.19
  8. Yefeng Yin · 2 shared papers, 2019–2020 · strength 0.19
  9. Orkhan Isayev · 1 shared paper, 2022 · strength 0.16
  10. Jens Thomas Siveke · 1 shared paper, 2022 · strength 0.16
  11. Alexandr V. Bazhin · 3 shared papers, 2013–2016 · strength 0.15
  12. Ivan Shevchenko · 3 shared papers, 2013–2015 · strength 0.14
  13. Jan Goesta D’Haese · 2 shared papers, 2015–2016 · strength 0.12
  14. Jan Schmidt · 2 shared papers, 2014–2015 · strength 0.09
  15. Sabine Soltek · 2 shared papers, 2013–2015 · strength 0.09
  16. Yiqiao Luo · 1 shared paper, 2019 · strength 0.08
  17. Tim Bleul · 1 shared paper, 2015 · strength 0.06
  18. Ralph Rühl · 1 shared paper, 2015 · strength 0.06
  19. Werner Hartwig · 1 shared paper, 2015 · strength 0.05
  20. Jens Martin Werner · 1 shared paper, 2015 · strength 0.05
  21. Eduard Ryschich · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.